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Background. Aortic stiffness changes the flow pattern of circulating blood causing microvascular damage to different end-organ
tissues, such as brain cells. The relationship between aortic stiffness measured by pulse wave velocity (PWV) and serum ischemic
brain injury biomarker N-methyl-D-aspartate receptor antibody (NR2Ab) levels in aortic valve replacement has not been assessed.
Methods. Patients undergoing aortic valve replacement (AVR) for aortic stenosis (AS) had their PWV and NR2Ab serum levels
measured preoperatively. We analyzed PWV and NR2Ab in two ways: (1) as continuous variables using the actual value and (2) as
dichotomous variables (PWV-norm and PWV-high groups) and (NR2Ab-low and NR2Ab-high groups). Results. Fifty-six patients
(71 ± 8.4 years) were included in this study. The NR2Ab level (ng/mL) was significantly higher in the PWV-high group (𝑛 = 21)
than in PWV-norm group (𝑛 = 35; median 1.8 ± 1.2 versus 1.2 ± 0.7, resp., 𝑃 = 0.003). NR2Ab level was positively associated with
PWV and negatively associated with male gender. Multiple regression revealed PWV independently related to NR2Ab level, and
PWV cut-off was associated with a 7.23 times increase in the likelihood of having high NR2Ab (>1.8 ng/mL). Conclusion. Higher
PWV in patients with surgical aortic stenosis is associated with higher levels of the ischemic brain biomarker NR2Ab.
1. Introduction
Aortic stiffness is an emerging risk factor for cardiovascular
disease and it is related to age [1]. Aortic stiffness assessed
by pulse wave velocity (PWV) is an independent predictor of
cardiovascular (CV) and all-cause mortality in hypertension
[2], diabetes mellitus [3], and end stage renal disease [4].
Carotid-femoral PWV is considered the gold standard for
measuring arterial stiffness [1]. In 2010, the “Reference Values
for Arterial Stiffness Collaboration” published the reference
and normal values for PWV based on European population
(eight countries) of more than 16 thousands subjects [1].
These reference values can be employed to investigate the
relationship between arterial stiffness and other end points
in different populations.
Vascular autoregulationmaintains a relatively stable brain
blood flow despite blood pressure changes. In addition,
regional increases in brain activity cause regional surges in
blood demand and influences regional increases in blood
flow, a process known as functional hyperemia [5]. Effi-
cient global brain circulation, autoregulation, and functional
hyperemia depend not only on blood volume and blood
pressure but also critically on intact, healthy, and reactive
cerebral blood vessels [5].
In a longitudinal study of 1,715 essential hypertensive
patients with a mean follow-up of 7.9 years, PWV inde-
pendently predicted fatal stroke after full adjustment for
classic cardiovascular risk factors, including age, cholesterol,
diabetes, smoking, mean blood pressure, and pulse pressure
[6]. Furthermore, Okuyama et al. found that aortic stiffness
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is an independent predictor of stroke recurrence after a mean
follow-up period of 459 days for 201 stroke patients [7].
Moreover, there is an association between aortic PWV and
intracranial large artery disease in patients with history of
ischemic stroke [8].Themechanism of progressive neurolog-
ical deficit in patients with acute deep subcortical infarction
is unknown; however, Saji et al. have recently hypothesized
that PWV may be part of such a mechanism, as they found
that PWV was independently associated with progressive
neurological deficit in these patients [9]. As the relationship
between aortic stiffness and cerebrovascular outcome was
established, additional studies on the mechanisms and medi-
ators of this relationship using advanced imaging technology
were more prevalent. PWV is independently associated with
the manifestations of cerebral small vessel disease, such as
silent brain infarction and white matter disease, which are
risk factors for stroke [10–12]. Using advanced magnetic
resonance imaging (MRI) arterial spin labeling (ASL) tech-
nique, Tarumi et al. found a significant inverse relationship
between aortic stiffness and cerebral perfusion of frontal
white matter [13] and the occipitoparietal region [14]. The
damaging effect of vascular risk factors including central
arterial stiffness on the brain tissue by different mechanisms
such as chronic hypoperfusion has been investigated widely
using imaging technologies which are expensive and have
practical limitations [15, 16].Therefore, identifying a practical
and cheaper biomarker linking vascular pathology to brain
injury would be clinically vital.
Ischemic brain biomarkers have been extensively studied
for decades to identify a reliable and practical biomarker
equivalent to the cardiac troponins. There are about 70
ischemic brain injury biomarkers which have been studied
over the last four decades; none of them is currently used in
clinical practice for the diagnosis of brain ischemia [17–19].
Some of these biomarkers have been identified as potential
candidates for future studies involving ischemic injuries,
including NR2Ab, S-100, tau protein, NSE, brain natriuretic
peptide, and CRP [17, 18, 20–24]. Our literature search could
not find any study investigating brain biomarkers in chronic
cerebral ischemia. Therefore, the predictive value of such
biomarkers and their association with other potential risk
factors of chronic brain ischemia, such as aortic stiffness, is
an area of research interest.
Death or ischemia of neural cells causes degradation of
subunits (NR2) of the NMDA receptor, and the proteolytic
fragments start to circulate in the bloodstream. This in turn
stimulates the immune system to produce antibodies against
these NR2 fragments (NR2Ab), which can be assayed in
blood samples [25]. Adult patients with acute or recent
ischemic stroke have elevated blood levels of NR2Ab that
correlate with the amount of brain damage or the presence of
recent stroke in comparison to controls. Test sensitivity and
specificity for diagnosing ischemic stroke within 3 hours of
symptom onset were 100% and 89% for cut-off of 1.8 ng/mL
and 97% and 98% for cut-off point of 2.0 ng/mL [26, 27].
Bokesch et al. found that preoperative serum concentrations
ofNR2Ab are predictive of severe neurological adverse events
after cardiac surgery in high-risk adult and that patients
with NR2Ab level ≥2.0 ng/mL (selected based on the above
study [26]) preoperatively were nearly 18 times more likely to
develop neurological event postoperatively than patients with
NR2Ab <2.0 ng/mL [20]. Physiologically, the production of
these antibodies may take time, and they last in the blood for
manymonths after ischemia, making the clinical applications
of this test not limited to acute setting [17, 19, 28]. This
supports the hypothesis of investigating NR2Ab level inmore
chronic pathologies such as arterial stiffness. NR2Ab is a
potential brain injury biomarker, but its relationship with
aortic stiffness has never been investigated.
The relationship between aortic stiffness and cardiovas-
cular and cerebrovascular adverse outcome has been estab-
lished. Therefore, identifying a biomarker (such as NR2AB)
linking the vascular cause (such as aortic stiffness) to end-
organ damage (such as the brain) is of clinical importance.
2. Materials and Methods
2.1. Patient Population and Overview. Ethical approval (11/
H0709/3) and participant informed consent were obtained
prior to the study. From June 2010 to August 2012, patients
planning to undergo AVR for severe aortic stenosis were
eligible. Exclusion criteria included (1) aortic dissection; (2)
severe aortic regurgitation; (3) thoracic aorta (more than
just the root) or abdominal aortic aneurysm; (4) Marfan’s
syndrome; (5) a history of stroke or transient ischemic attack
(TIA) in the last year.
Carotid-femoral PWV was used to assess aortic stiffness.
To measure NR2Ab, blood samples were collected from each
patient preoperatively [20, 26]. Based on patients’ preopera-
tive PWVmeasurement and the published European normal
values of PWV for the matched age group [1], patients were
divided into two groups:
(a) PWV-norm group: with PWV equal to or below
normal reference value for their respective age group.
(b) PWV-high group: with PWV above the normal refer-
ence value for their respective age group.
2.2. Pulse Wave Velocity Measurement Protocol. Abstinence
from tea, coffee, and tobacco for at least 2 hours prior to mea-
surement was ensured. Patients were asked to rest for at least
10 minutes in a quiet, temperature-controlled room (22–25
degree Celsius) before the hemodynamicmeasurements were
taken. Automated digital sphygmomanometer (Criticare sys-
tem, Model 506N3, Waukesha, USA) was used to measure
brachial blood pressure (BP) and heart rate. Separated by the
PWVmeasurements, two readings of BP were taken, and the
mean was used for analysis. Automatic applanation tonom-
etry system (the SphygmoCor Vx system, AtCor Medical,
Australia) was employed to measure aortic PWV (carotid-
femoral PWV). While resting in a supine position, ECG-
gated pulse waveforms were obtained sequentially from the
common carotid and then femoral arteries by application
of applanation tonometry. Propagation time of the pulse
wave was measured from the foot of the carotid waveform
to that of the femoral waveform referenced to the R-wave
on the recorded ECG. The travelling distance of the wave-
form was measured in millimeters externally by subtracting
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the distance between the suprasternal notch and carotid
site from the distance between the suprasternal notch and
femoral site. The system software of the SphygmoCor device
calculated PWV automatically in meters per second (m/s) by
dividing the travelled distance by the propagation time.Three
to five readings of PWV were obtained per patient; PWV
was determined by averaging the measurements that met the
quality control parameters (as set by SphygmoCor Clinical
User Manual).
2.3. NR2AbBiomarker. Blood sampleswere collected 18–24 h
prior to surgery from 52 patients out of 56 patients who
had their PWV measured. Blood samples were centrifuged
immediately with 3000 rpm at 20∘C for 10 minutes, and
then serum samples were separated and frozen at −80∘C.
Frozen samples were processed with ELISA technique using
Gold Dot NR2 Antibody Test (CIS Biotech, Inc., Atlanta,
GA). This was done according to the manufacturer’s pro-
cedure and as previously published [27]. In brief, frozen
samples were thawed at −8∘C. Serum sample was diluted
1 : 50 (20𝜇L of serum sample + 980 𝜇L of working buffer)
into 3mL tubes. Microplates were washed with working
buffer for 5 minutes at 37∘C on a shaker. We then added
100 𝜇L of calibrators, negative controls, positive controls,
and prepared diluted sera to microplates coated with NR2
peptide and incubated the plates for 30 minutes at 37∘C on a
shaker. After incubation, the microplates were washed with
buffer, and 100 𝜇L (1 : 1000 dilution) of A-HRP (antihuman
horseradish peroxidise) was added to the microplates and
incubated for 30 minutes at 37∘C on a shaker to structure
the immunocomplex. The microplates were then washed
with working buffer and distilled water and 100 𝜇L of TMB
(tetramethylbenzidine) substrate was added and incubated in
darkness at room temperature for 10 minutes to accomplish
colour development. Colour reaction stopped by adding Stop
Reagent (100 𝜇L) and gentle shaking for 30 seconds.The optic
density was measured within 10 minutes at 450 nm/630 nm
dual wave microplate reader. The NR2A antibodies in serum
were measured by using a standard calibration curve of the
absorbance obtained for each calibrator 𝑋-axis versus the
NR2 antibody concentration in ng/mL on the 𝑌-axis.
2.4. Statistical Analysis. Statistical analysis was conducted
using IBM SPSS 20.0 software package (IBM Corporation,
Armonk, NY, USA). Patient characteristics and results are
expressed as means ± standard deviation, except for NR2Ab,
which is expressed as median± standard deviation, for con-
tinuous variable and as frequencies for categorical variables.
𝑃 values <0.05 were considered statistically significant. Nor-
mality testing was carried out on all variables studied. For the
purpose of the regression analysis, nonnormally distributed
NR2Ab levels were log-transformed.
PWV was analyzed as a continuous variable to verify our
hypothesis. In addition, it was also analyzed as a dichoto-
mous variable (PWV-norm group versus PWV-high group).
NR2Ab was analyzed as a continuous variable by using
the actual serum level to verify our hypothesis. Additional
analysis as a dichotomous variable was performed using the
median value of the NR2Ab level of the PWV-high group
(1.8 ng/mL) as a cut-off point to classify patients into NR2Ab-
low (<1.8 ng/mL) and NR2Ab-high (≥1.8 ng/mL) groups;
this cut-off was previously tested [26]. Comparative analysis
between the two PWV groups (PWV-norm and PWV-high)
and the two NR2Ab groups (NR2Ab-low and NR2Ab-high)
was carried out using an independent samples t-test or
nonparametric equivalent (Mann-Whitney 𝑈 test) for con-
tinuous variables, and Pearson Chi-square or Fisher’s exact
tests were carried out for categorical variables. Correlation
analysis between variables was conducted using Spearman’s
rank-order correlation and point biserial correlation (for
dichotomous variables), while Phi test was used between two
dichotomous variables (2 × 2). Simple regression (linear or
logistic) between end points and other variables were used
to identify potential predictors. All variables significant by
simple regression or correlation, in addition to age and gen-
der, were then included in two models of multiple regression
analysis (enter method): (1) Model 1, including PWV as a
continuous predictor; and (2) Model 2, including PWV cut-
off as a dichotomous predictor.
3. Results
3.1. Descriptive Results. Fifty-six patients (16 females) with
a mean age of 71 ± 8.4 years were recruited for this study.
No mortality or severe neurological event (stoke or TIA) was
recorded after amean follow-up period of 409±159days post-
operatively (post-AVR). Table 1 summarizes the demographic
and clinical data of the patients and the correlation of these
variables with NR2Ab level and the NR2Ab 1.8 ng/mL cut-
off. NR2Ab was significantly associated with aortic stiffness
(PWV), while the NR2Ab 1.8 ng/mL cut-off, in addition to
PWV, was negatively associated with male gender.
3.2. NR2Ab and Aortic Stiffness. The overall mean PWV
value was 9.3 ± 2.2m/s and, as expected, it was significantly
related to different age groups (𝑃 = 0.001, analysis of
variance [ANOVA]) but not gender (𝑃 = 0.34). Thirty-
five (62.5%) patients were classified in the PWV-norm group
and 21 patients (37.5%) were in the PWV-high group. There
was no significant difference between the two groups of
PWV with respect to age, gender, classical hemodynamic
measurements, aortic valve mean gradient, aortic valve peak
gradient and aortic valve area, estimated IQ,, and other
clinical characteristics (data is not shown).
The NR2Ab level (ng/mL) was significantly higher in the
PWV-high group than in the PWV-norm group (median
1.8 ± 1.2 versus 1.2 ± 0.7, resp., 𝑃 = 0.003), and PWV (m/s)
was significantly higher in the NR2Ab-high group (𝑛 = 17)
than in the NR2Ab-low group (𝑛 = 35; mean 10.9±2.1 versus
9.1 ± 2.2, 𝑃 = 0.05). Table 1 demonstrates the significant
correlations between NR2Ab and PWV value (𝑟 = 0.28, 𝑃 =
0.05), NR2Ab and PWVcut-off (𝑟 = 0.42,𝑃 = 0.002), NR2Ab
1.8 ng/mL cut-off and PWV value (𝑟 = 0.27, 𝑃 = 0.05),
and NR2Ab 1.8 ng/mL cut-off and PWV cut-off (Phi = 0.43,
𝑃 = 0.002).
To confirm the findings of the correlation analysis,
simple linear regression between NR2Ab and other variables
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Table 1: Demographic and clinical characteristics and their correla-
tion with NR2Ab level and NR2Ab 1.8 ng/mL cut-off.
Variables Total(𝑛 = 56)
NR2Ab
level a𝑟
NR2Ab 1.8 ng/mL
cut-off a𝑟
PWV (m/s) 9.3 ± 2.2 0.28∗ 0.27∗
PWV cut-off — 0.42∗∗ 0.43∗∗
NR2Ab 1.8 ng/mL
cut-off — 0.74
∗∗ 1.00
Age (years) 71 ± 8.4 −0.08 0.01
Gender (male) 40 (71.4%) −0.26 −0.32∗
DM [𝑛 (%)] 8 (14.3%) 0.14 0.09
Smoking [𝑛 (%)] 2 (3.6%) −0.08 0.02
BMI (kg/m2) 27.2 (4.2) −0.21 −0.23
SBP (mmHg) 136 ± 24 −0.03 0.02
DBP (mmHg) 76 ± 11 −0.22 −0.24
PP (mmHg) 62 ± 15 0.11 0.21
MAP (mmHg) 97 ± 12 −0.11 −0.15
Cholesterol
(mmol/L) 4.5 ± 1.2 0.23 0.22
Hypertension
[𝑛 (%)] 38 (67.9%) 0.18 0.14
Statin treatment
[𝑛 (%)] 38 (67.9%) 0.10 0.02
PVD [𝑛 (%)] 2 (3.6%) 0.12 0.25
EuroSCORE
(logistic) 5.5 ± 4.3 0.04 0.18
AVA (cm2) 0.73 ± 0.2 −0.09 −0.10
AVMG (mmHg) 48 ± 13 0.00 −0.06
AVPG (mmHg) 82 ± 24 0.14 0.01
EF 59 ± 15 0.22 0.06
∗Correlation is significant at the 0.05 level (2-tailed); ∗∗correlation is signif-
icant at the 0.01 level (2-tailed). aCorrelation coefficient, bold values indicate
statistical significance. Abbreviations: AVA, aortic valve area; AVMG, aortic
valve mean gradient; AVPG, aortic valve peak gradient; BMI, body mass
index; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, Ejection
fraction; MAP, mean arterial blood pressure; NR2Ab, N-methyl-D-aspartate
(NMDA) receptor antibodies; PP, pulse pressure; PVD, peripheral vascular
disease; PWV, pulse wave velocity; SBP, systolic blood pressure.
(age, gender, mean arterial pressure, body mass index, smok-
ing diabetes mellitus, ejection fraction, aortic valve peak
gradient, aortic valvemean gradient, aortic valve area, choles-
terol, triglycerides, and PWV) was performed to identify
potential predictors of NR2Ab level (Table 2). In this simple
linear regression analysis, the relationship between NR2Ab
(log transformation) was significantly related only to PWV
value (continuous), PWV cut-off (dichotomous), and gender.
Variables with significant linear regression or correlation,
in addition to age, were included in a multiple regression
(enter method) analysis (Table 2). Model 1 of the multiple
linear regression (includes PWV, age, and gender) statistically
significantly predicts NR2Ab (F = 3.33, 𝑃 = 0.03), and 17.2%
of variance in NR2Ab can be explained by changes in these
variables. PWV was independently related to NR2Ab level
(beta = 0.37;𝑃 = 0.022).Model 2 of themultiple linear regres-
sion (including PWV cut-off, age, and gender) statistically
Table 2: Simple and multiple linear regression analysis to identify
variables that independently predict NR2Ab level.
Predictors NR2Ab level beta (𝑃 value)
Simple linear regression
PWV value 0.27 (0.05)
PWV cut-off 0.39 (<0.01)
Age −0.05 (0.71)
Gender (male) −0.27 (0.05)
DM 0.08 (0.57)
Smoking −0.12 (0.38)
BMI (kg/m2) −0.2 (0.15)
MAP (mmHg) −0.16 (0.26)
Cholesterol (mmol/L) 0.09 (0.67)
EuroSCORE (logistic) 0.07 (0.49)
AVA (cm2) −0.09 (0.55)
AVMG (mmHg) −0.01 (0.92)
AVPG (mmHg) −0.06 (0.66)
EF 0.03 (0.83)
Multiple linear regression (Model 1)
PWV value 0.37 (0.02)
Age −0.25 (0.12)
Gender (male) −0.21 (0.12)
Multiple linear regression (Model 2)
PWV cut-off 0.37 (<0.01)
Age −0.09 (0.46)
Gender (male) −0.21 (0.11)
Values are shown as standardized beta coefficient (𝑃 value); bold val-
ues indicate statistical significance. Abbreviations: AVA, aortic valve area;
AVMG, aortic valve mean gradient; AVPG, aortic valve peak gradient; BMI,
body mass index; DM, diabetes mellitus; EF, Ejection fraction; MAP, mean
arterial blood pressure; NR2Ab, N-methyl-D-aspartate (NMDA) receptor
antibodies; PWV, pulse wave velocity.
significantly predicts NR2Ab level (F = 4.13, 𝑃 = 0.01), and
20.5% of variance in NR2Ab can be explained by changes in
these variables. The PWV cut-off was independently related
to NR2Ab level (beta = 0.37; 𝑃 = 0.008).
Additional analysis was performed to ascertain the effects
of PWV on the likelihood of patients being in the NR2Ab-
high group (≥1.8 ng/mL). First, simple logistic regression
was conducted to confirm the findings from the correlation
analysis; only PWV cut-off and gender were statistically
significant, while the PWV value was clinically significant
(Table 3). Therefore, only PWV (the predictor of interest)
and age and gender (classical variables) were included in
the multiple logistic models. In Model 1 of the multiple
logistic regression (Table 3), though the entire model was
statistically significant (𝑃 = 0.017) and was explained to
be 24.7% (Nagelkerke 𝑅2) of the NR2Ab variance, the PWV
value itself was not a significant predictor, while gender was
the only significant predictor, of which male gender was
protective (odds ratio [OR] below 1). Model 2, using PWV as
a dichotomous variable (PWV-norm versus PWV-high), was
even more significant than Model 1. The logistic regression
model was statistically significant (𝑃 = 0.002). The model
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Table 3: Simple and multiple logistic regression analysis to identify
variables that independently predict patients with high NR2Ab
(NR2Ab 1.8 ng/mL cut-off).
Predictors NR2Ab 1.8 ng/mL cut-off
OR (95%CI) 𝑃-value
Simple logistic regression
PWV value 1.29 (0.97–1.71) 0.08
PWV cut-off 6.93 (1.91–25.17) <0.01
Age 1.0 (0.93–1.01) 0.96
Gender (male) 0.18 (0.05–0.67) 0.01
DM 1.63 (0.33–8.01) 0.54
Smoking 0.94 (0.33–2.65) 0.92
BMI (kg/m2) 0.88 (0.79–1.02) 0.09
MAP (mmHg) 0.97 (0.92–1.02) 0.31
Cholesterol (mmol/L) 1.63 (0.84–3.19) 0.14
EuroSCORE (Logistic) 1.09 (0.95–1.25) 0.21
AVA (cm2) 0.35 (0.01–6.98) 0.49
AVMG (mmHg) 0.99 (0.64–1.03) 0.69
AVPG (mmHg) 1.0 (0.97–1.02) 0.96
EF 1.0 (0.96–1.05) 0.72
Multiple logistic regression (Model 1)
PWV value 1.4 (0.94–2.06) 0.09
Age 0.95 (0.86–1.05) 0.32
Gender (male) 0.21 (0.05–0.79) 0.02
Multiple logistic regression (Model 2)
PWV cut-off 7.23 (1.74–30.1) <0.01
Age 0.98 (0.91–1.06) 0.66
Gender (male) 0.19 (0.04–0.8) 0.02
Values are shown as odd ratio (OR) and 𝑃 value; bold values indicate
statistical significance. Abbreviations: AVA, aortic valve area; AVMG, aortic
valve mean gradient; AVPG, aortic valve peak gradient; BMI, body mass
index; DM, diabetes mellitus; EF, Ejection fraction; MAP, mean arterial
blood pressure; NR2Ab, N-methyl-D-aspartate (NMDA) receptor antibod-
ies; PWV, pulse wave velocity.
explained 35.5% (Nagelkerke 𝑅2) of the variance in NR2Ab
and correctly classified 73.1% of cases, the positive predictive
value was 66.6%, and the negative predictive value was 74.4%.
In this model, only PWV cut-off was statistically significant,
as changing the status of PWV from normal to high was
associated with a 7.23 times increased likelihood of having
high NR2Ab (>1.8 ng/mL; Table 3).
4. Discussion
Most of the previous studies focused on the predictive value
of the NR2Ab in acute ischemia (stoke and TIA) [26, 27];
however, little has been done to explore the predictive value
in more chronic cerebrovascular pathologies such as arterial
stiffness. In our 52 patients, NR2Ab levels were not related
to age. Conversely, male gender was related to lower NR2Ab
level. Furthermore, our results showed that only two vari-
ables, gender and PWV, were associated with NR2Ab level;
male gender had a negative association, while PWV (aortic
stiffness) had a positive association. To test the objective
of whether PWV is related to NR2Ab biomarker level,
correlation andmultiple regression analyses were performed.
These analyses revealed that PWV value was significantly
related to and independently predicted NR2Ab but not the
NR2Ab 1.8 ng/mL cut-off. Grouping patients according to
their PWV into PWV-norm and PWV-high (PWV cut-off)
increased the significance of the relationship with NR2Ab,
PWV cut-off was an independent predictor of NR2Ab level,
and it was associated with a 7.23 times increased likelihood of
having high NR2Ab > 1.8 ng/mL.
It is known that high PWV is significantly associated
with cerebral small vessel disease [29–31] and NR2Ab is
a potential ischemic brain injury biomarker [25–27]. The
positive relationship between NR2Ab and PWV may be
explained by the hemodynamic ischemic effect of arterial
stiffness on brain tissue and subsequent release of proteolytic
fragments of NR2 subunits of the NMDA receptors and the
formation of NR2Ab over time. This does not undermine
the importance of NR2Ab in acute ischemia, particularly
if serum levels are proportional to the size and severity of
the ischemia. For example, it was previously reported that
the mean NR2A/2B antibody level (ng/mL) in patients with
ischemic stroke was 5.01 ± 1.23 (range, 3.24–7.21), in patients
with TIA it was 4.02 ± 2.04 (range, 2.71–7.23), and in patients
with hypertension/atherosclerosis it was 1.72 ± 0.23, while
in controls it was only 1.49 ± 0.22 (range, 1.02–1.98) [26].
Our results are similar to the values of the atherosclerosis
and controls groups (median 1.8 ± 1.2 versus 1.2 ± 0.7 for
the PWV-high versus PWV-norm groups, resp.) as no patient
developed stroke or had a TIA.
There was no correlation between AS parameters, such
as AVA, AVMG, or AVPG, and NR2Ab level (Table 1). The
absence of such a relationship may indicate that AS has
no chronic ischemic effect on brain tissue. However, this
conclusion would be more concrete if we measured NR2Ab
levels postoperatively to determine if replacing a diseased
valve (AVR) has any effect onNR2Ab levels. To the best of our
knowledge, this is the first study to investigate and establish
a relationship between aortic stiffness (PWV) and NR2Ab
biomarker levels.
5. Limitations
NR2Ab level was only measured preoperatively; it may
be useful to measure sequential levels postoperatively to
determinewhether there is a change inNR2Ab level following
AVR. The effect of potential confounders, such as diabetes,
hypertension, and dyslipidemia, on the relationship between
aortic stiffness andNR2Ab requires amuch larger sample size
to be adequately evaluated.However, the aimof this studywas
to provide explorative preliminary data that can be used to
direct future studies.
6. Conclusions and Future Clinical Prospects
Higher PWV values in patients with surgical aortic stenosis
are associated with higher levels of the ischemic brain
biomarker NR2Ab.
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As for any predictor of disease condition, early identifi-
cation of patients at risk will facilitate regular monitoring,
risk stratification, and future planning and consideration
of potential therapies, if available. PWV is a predictor of
adverse cardiovascular and cerebrovascular outcomes, while
NR2Ab is a potential pathophysiological predictor of adverse
cerebrovascular outcomes. The association between two
predictors of common or different outcomes, for example,
between diabetes and hypertension or in our case between
PWV and NR2Ab, provides a better understanding of the
disease development process, facilitates the development of
future risk stratification models, and renders their clinical
use, to some degree, interchangeable.
This study offers a significant step forward in our knowl-
edge pertaining to end-organ damage in the presence of
increased aortic stiffness. Future cross-sectional studies with
larger sample sizes to adjust for potential confounders, such
as hypertension, diabetes, and dyslipidemia, are required
to establish or reject this relationship. Establishing such a
relationship in cross-sectional studies will warrant the need
for longitudinal studies to assess the predictive value of
NR2Ab level for clinical outcomes across different groups of
PWV values. Ultimately, this will move us a step closer to
discovering new clinical (PWV) and biochemical (NR2Ab)
predictors of neurocognitive outcomes, in addition to the
traditional risk factors currently in use.
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